Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3- gallate on human melanoma: Possible implications for the chemoprevention of melanoma

International Journal of Cancer

Volumn 114, Issue 4, 2005, Pages 513-521

  Nihal, Minakshi ^a   Ahmad, Nihal ^a   Mukhtar, Hasan ^a   Wood, Gary S ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Apoptosis; Bcl 2 family; Caspase; Cell cycle; EGCG; Green tea; Melanoma

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CYCLIN DEPENDENT KINASE; CYCLINE; EPIGALLOCATECHIN GALLATE; PROTEIN BAX; PROTEIN BCL 2;

AMELANOTIC MELANOMA; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOPROPHYLAXIS; CLONOGENESIS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TEA; UPREGULATION;

AGAR; ANTICARCINOGENIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 7; CASPASE 9; CASPASES; CATECHIN; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MELANOCYTES; MELANOMA; MEMBRANE POTENTIALS; MITOCHONDRIA; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS;

EID: 14844335699     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20785     Document Type: Article

References (33)

1. Keilholz U. Biochemotherapy of melanoma. Forum (Genova) 2003;13:158-69.
2. Demierre MF, Nathanson L. Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 2003;21:158-65.
3. Mukhtar H, Ahmad N. Green tea in chemoprevention of cancer. Toxicol Sci 1999;52:111-7
4. Rietveld A, Wiseman S. Antioxidant effects of tea: evidence from human clinical trials. J Nutr 2003;133:3285S-92S.
5. Siddiqui IA, Afaq F, Adhami VM, Ahmad N, Mukhtar H. Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 2004;6:571-82.
6. Meyskens FL Jr, McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, Gonzalez RI. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med 2001;31:799-808.
7. Park OJ, Surh YJ. Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicol Lett 2004;150:43-56.
8. Yang CS. Wang ZY. Tea and cancer. J Natl Cancer Inst 1993;85:1038-49.
9. Mahadevan D, Thanki N, Aroca P, McPhie P, Yu JC, Beeler J, Santos E, Wlodawer A, Heidaran MA. A divalent metal ion binding site in the kinase insert domain of the alpha-platelet-derived growth factor receptor regulates its association with SH2 domains. Biochemistry 1995;34:2095-106.
10. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
11. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
12. Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. J Nutr 2003;133:3262S-7S.
13. Senderowicz AM. Cell cycle modulators for the treatment of lung malignancies. Clin Lung Cancer 2003;5:158-68.
14. Nam NH, Parang K. Current targets for anticancer drug discovery. Curr Drug Targets 2003;4:159-79.
15. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
16. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
17. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-33.
18. Liu W, Bulgaru A, Haigentz M, Stein CA, Perez-Soler R, Mani S. The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics. Curr Med Chem Anti-Cane Agents 2003;3:217-23.
19. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003;4:721-9.
20. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644:229-49.
21. Wacheck V, Losert D, Gunsberg P, Vornlocher HP, Hadwiger P, Geick A, Pehamberger H, Muller M, Jansen B. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 2003;13:393-400.
22. Kruidering M, Evan GI. Caspase-8 in apoptosis: the beginning of "the end"? IUBMB Life 2000;50:85-90.
23. Derradji H, Baatout S. Apoptosis: a mechanism of cell suicide. In Vivo. 2003;17:185-92.
24. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004;5:27-36.
25. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46.
26. Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell 2002;111:923-25.
27. Roberts JM, Sherr CJ. Bared essentials of CDK2 and cyclin E. Nat Genet 2003;35:9-10.
28. Dai Y, Grant S. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Curr Oncol Rep 2004;6:123-30.
29. Borgne A, Golsteyn RM. The role of cyclin-dependent kinases in apoptosis. Prog Cell Cycle Res 2003;5:453-9.
30. Driscoll B, Buckley S, Barsky L, Weinberg K, Anderson KD, Warburton D. Abrogation of cyclin D1 expression predisposes lung cancer cells to serum deprivation-induced apoptosis. Am J Physiol 1999;276:L679-87.
31. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003;22:3092-8.
32. Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, Bond J, Hill L, Bataille V, Peters G, Kipling D, Wynford-Thomas D, Bennett DC. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 2003;95:723-32.
33. Yamamoto T, Hsu S, Lewis J, Wataha J, Dickinson D, Singh B, Bollag WB, Lockwood P, Ueta E, Osaki T, Schuster G. Green tea polyphenol causes differential oxidative environments in tumor versus normal epithelial cells. J Pharmacol Exp Ther 2003;307:230-6.